Illumina, Inc. vs Nutanix Inc — how do they compare? Illumina, Inc. trades at $270.94 (market cap $39.95B), while Nutanix Inc trades at $73.93 (market cap $19.78B). The key difference: Illumina, Inc. is far larger — about 2× Nutanix Inc's market cap, and Nutanix Inc is trading nearer its 52-week high, Illumina, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Nutanix Inc for 17 Days on average.
| ILMN | NTNX | |
|---|---|---|
Market Cap | $39.95B | $19.78B |
Volume | 3,169,503 | 1,717,619 |
Sector | Health | Technology |
52-Week High | $293.69 | $73.42 |
52-Week Low | $91.00 | $34.41 |
Typical Hold Time | 83 Days | 17 Days |
Enterprise Value | $41.31B | $18.94B |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
Nutanix (NTNX) trades at $73.24, down slightly by 0.25% today, but maintains a bullish technical outlook with strong analyst support. The company demonstrates robust fundamentals with consistent earnings beats, including Q2 2026 EPS of $0.60 beating expectations of $0.49, and impressive profitability with an 86.8% gross margin. Recent Gartner Magic Quadrant recognitions highlight competitive strength in virtualization and container management platforms, supporting positive market sentiment.
The investment outlook remains positive with a consensus price target of $76.11 representing 4% upside potential. Key opportunities include external storage partnerships and AI growth initiatives, while risks involve high valuation multiples (EV/EBITDA of 46.22) and negative ROE of -395.76%. Institutional ownership trends and 62.5% analyst buy ratings suggest continued Wall Street confidence in the company's execution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Nutanix, Inc. is a global leader in cloud software and hyperconverged infrastructure (HCI) solutions. The company's platform converges computing, virtualization, and storage into a single, seamless software-defined solution, enabling private, hybrid, and multi-cloud environments. Nutanix helps organizations simplify data center operations, manage their applications across various cloud platforms, and reduce IT complexity, positioning it as a key enabler of modern hybrid cloud strategies.
Read more on NTNX →